openPR Logo
Press release

PharmSource - Bio/Pharma CapEx Trends 2016 | Now Available at Researchmoz.us

12-27-2016 03:37 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Bio/Pharma CapEx

Researchmoz added Most up-to-date research on "PharmSource - Bio/Pharma CapEx Trends 2016" to its huge collection of research reports.

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, its clear that bio/pharma companies would rather make than buy.

According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

Scope

- Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
- It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
- It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=903182

Reasons to buy

- The 16-page report provides important insight that you wont find in any other source. This report is required reading for -
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Table of Contents
Executive Summary 1
Introduction 2
CapEx Overview 3
CapEx Relative to Other Financial Indicators 6
Nature of Capital Expenditure - What Is Being Built 8
What It Means 10
Appendix 12
Recently Announced and Completed Investments by Global Bio/Pharma Companies 12
Manufacturing Investments in Emerging Markets 2014-2021 by Global Bio/Pharma Companies 14
Selected CapEx Investments by Generic Companies 2014 Onwards 15

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=903182

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PharmSource - Bio/Pharma CapEx Trends 2016 | Now Available at Researchmoz.us here

News-ID: 401435 • Views:

More Releases for CMO

Healthcare Cmo Market Size Analysis by Application, Type, and Region: Forecast t …
USA, New Jersey- According to Market Research Intellect, the global Healthcare Cmo market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The healthcare contract manufacturing organization (CMO) market is witnessing steady expansion due to increasing demand for outsourced pharmaceutical and medical device production. Rising healthcare costs
New Fractional CMO Agency Offers Fractional CMO Services to Businesses of All Si …
Modern CMO, a new fractional CMO agency, has officially launched to offer businesses of all sizes access to expert-level marketing strategies and a team of experienced CMOs to lead their marketing initiatives. Modern CMO's fractional CMO services provide businesses with access to the same level of expertise as a full-time CMO, without the costly overhead expenses. This means that businesses can tap into Modern CMO's pool of highly skilled marketing professionals
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial
Healthcare CMO Market
Healthcare CMO Market to 2027 - Global Analysis and Forecasts By Service (Pharmaceutical Contract Manufacturing Services and Medical Device Contract Manufacturing Services), and Geography The global healthcare CMO market is expected to witness substantial growth. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable
CMO Scorecard Review: CMO Performance & Outsourcing of NDA Approvals 2017
Recently, Market Research Hub (MRH) has added a fresh report which focuses on the CMO industry’s authoritative analysis of manufacturing of NDA approvals. The research report focusing on the CMO Scorecard and is titled as, “PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2017 Edition”. This CMO scorecard was assembled through hundreds of professional hours of research and analysis, and is comprised in a 40-page report. Request
CMO Scorecard Review: CMO Performance & Outsourcing of NDA Approvals 2017
Recently, Market Research Hub (MRH) has added a fresh report which focuses on the CMO industry’s authoritative analysis of manufacturing of NDA approvals. The research report focusing on the CMO Scorecard and is titled as, “PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2017 Edition”. This CMO scorecard was assembled through hundreds of professional hours of research and analysis, and is comprised in a 40-page report. Request